σ-ligands can kill tumor cells. Previously we have shown that a short in vitro incubation of C6
tumor cells with σ-ligands (24 h) results in a dose-dependent increase of cellular 18F-FDG …

σ-Receptors are strongly overexpressed in most rodent and human tumors and are
proliferation markers. To evaluate the potential of a radiolabeled σ1-ligand for therapy …

A series of biodistribution studies were conducted with the radiotracer,[18F] N-(4′-
fluorobenzyl)-4-(3-bromophenyl) acetamide,[18F] 1 in nude mice bearing tumor xenografts …

The development of sigma (σ) receptor radioligands has become the focus of research over
the past few years due to their potential uses in nuclear medicine. It has been shown that a …

The significant presence of nontumor cell populations within tumors can complicate the
assessment of in vivo tumor metabolism during therapy. To more clearly define the impact of …

Our objective was to study 2 radioligands for visualization of σ-receptors with PET. Methods:
Two radioligands—σ1-selective 11C-1-(3, 4-dimethoxyphenethyl)-4-(3-phenylpropyl) …

The σ2-receptor has been shown to be upregulated in proliferating tumors cells. The
purpose of this study was to compare 3′-deoxy-3′-18F-fluorothymidine (18F-FLT) and 2 …

Abstract Background Sigma2 (σ 2) receptors are highly expressed in cancer cell lines and in
tumours. Two novel selective 18 F-phthalimido σ 2 ligands, 18 F-SIG343 and 18 F-SIG353 …

High overexpression of sigma (σ) receptors (σ1 and σ2 subtypes) in a variety of human solid
tumors has prompted the development of σ receptor-targeting radioligands, as imaging …

Radiopharmaceuticals that can target the random metastatic dissemination of melanoma
tumors may present opportunities for imaging and staging the disease as well as potential …